Bluetongue vaccines: The past, present and future

Expert Review of Vaccines

Volumn 8, Issue 2, 2009, Pages 191-204

  Bhanuprakash, V ^a   Indrani, B K ^b   Hosamani, M ^a   Balamurugan, V ^a   Singh, R K ^a  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^b Advinus Therapeutics Private Limited Bangalore   (India)

Author keywords

Antiviral; Bluetongue; Control; New generation vaccine; Prophylactic; Therapeutic

Indexed keywords

BLUETONGUE ORBIVIRUS VACCINE; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LIVE VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6C2A.4.2; MONTANIDE ISA 206; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; PROTEIN VP2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY RESPONSE; BLUETONGUE ORBIVIRUS; DRUG QUALITY; DRUG SAFETY; IMMUNOGENICITY; INFECTION CONTROL; LACTATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SHEEP DISEASE; STRAIN DIFFERENCE; TERATOGENICITY; VACCINATION; VACCINE PRODUCTION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; ANIMALS, DOMESTIC; ANIMALS, WILD; BLUETONGUE; BLUETONGUE VIRUS; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 60349097397     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.8.2.191     Document Type: Review

References (123)

1. La fievre catarrhale du mouton (bluetongue). In: Institut D'elevage et de Medecine Veterinaire des Pays Tropicaux (IEMVT), Etude et Syntheses. Lefevre PC, Desoutter D (Eds).Montpellier, France 117 (1988).
2. Howell PG, Verwoerd DW. Bluetongue virus. Virol. Monogr. 9, 35-74 (1971).
3. Parsonson IM, Thomson LH, Walton TE. Experimentally induced infection with bluetongue virus serotype 11 in cows. Am. J. Vet. Res. 55, 1529-1534 (1994).
4. Menzies FD, McCullough SJ, McKeown IM et al. Evidence for transplacental and contact transmission of bluetongue virus in cattle. Vet. Rec. 203-209 (2008).
5. Muller H. The significance of the structural characteristics of the agent for the problems of immunization against bluetongue. Tierarztl. Prax. 19(6), 91-95 (1991).
6. Roberts DH. Bluetongue: a review. State Vet. J. 44(124), 66-80 (1990).
7. Davies FG, Mungai JN, Pini A. A new bluetongue virus serotype isolated in Kenya. Vet. Microbiol. 31(1), 25-32 (1992).
8. Walton TE. The history of bluetongue and a current global overview. Vet. Ital. 40 (3), 31-38 (2004).
9. Savini G, Hamers C, Conte A et al. Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle. Vet. Microbiol. 133(1-2), 1-8 (2009).
10. Saegerman C, Berkvens D, Mellor PS. Bluetongue epidemiology in the European Union. Emerg. Infect. Dis. 14(4), 539-544 (2008).
11. Sreenivasulu D, Subba Rao MV, Reddy YN, Gard GP. Overview of bluetongue disease, viruses, vectors, surveillance and unique features: the Indian sub-continent and adjacent regions. Vet. Ital. 40(3), 73-77 (2004).
12. Zhang N, Li Z, Zhang F, Zhu J. Studies on bluetongue disease in the People's Republic of China. Vet. Ital. 40(3), 51-56 (2004).
13. Balasuriya UB, Nadler SA, Wilson WC et al. The NS3 proteins of global strains of bluetongue virus evolve into regional topotypes through negative (purifying) selection. Vet. Microbiol. 126(1-3), 91-100 (2008).
14. Pedley S, Mohamed MEH, Mertens PPC. Analysis of genome segments from six different isolates of bluetongue virus using RNA-RNA hybridization: a generalized coding assignment for bluetongue viruses. Virus Res. 10, 381-390(1988).
15. Grimes JM, Burroughs JN, Gouet P et al. The atomic structure of the bluetongue virus core. Nature 395, 470-478 (1998).
16. Nason EL, Rothagel R, Mukherjee SK et al. Interactions between the inner and outer capsids of bluetongue virus. J. Virol. 78, 8059-8067 (2004).
17. Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S. Vaccines against bluetongue in Europe. Comp. Immunol. Microbiol. Infect. Dis. 31, 101-120 (2008).
18. Verwoerd D, Erasmus BJ. Bluetongue. In: Infectious Diseases of Livestock (2nd Edition). Coetzer JA, Tustin RC (Eds). Oxford University Press, Cape Town, South Africa 1201-1220 (2004).
19. Parker J, Herniman K A, Gibbs EP, Sellers RF. An experimental inactivated vaccine against bluetongue. Vet. Rec. 96(13), 284-287 (1975).
20. Ramakrishnan M, Pandey AB, Singh KP, Singh R, Mehrotra ML. Immune responses and protective efficacy in sheep immunized with hydroxylamine inactivated bluetongue virus vaccines. Vet. Ital. 41(3), 149-155 (2005).
21. Campbell CH, Barber TL, Knudsen RC, Swaney LM. Immune response of mice and sheep to bluetongue virus inactivated by gamma irradiation. Prog. Clin. Biol. Res. 178, 639-647 (1985).
22. Jeggo MH, Wardley RC. Production of murine cytotoxic T lymphocytes by bluetongue virus following various immunization procedures. Res. Vet. Sci. 33(2), 212-215 (1982).
23. Caporale V, Emidio B, di Nicolussi P et al. Efficacy and safety studies on an inactivated vaccine against bluetongue virus serotype 2. Vet. Ital. 40(4), 640-644 (2004).
24. Berry LJ, Osburn BI, Stott JL, Farver T, Heron B, Patton W. Inactivated bluetongue virus vaccine in lambs: differential serological responses related to breed. Vet. Res. Commun. 5(3), 289-293 (1982).
25. Stevens DR, Stott J, Osburn BI, Giles R, Wiesehahn GP, Barber TL. Potency and efficacy of inactivated bluetongue virus vaccines. Prog. Clin. Biol. Res. 178, 649-652 (1985).
26. Stott JL, Osburn BI, Barber TL. The current status of research on an experimental inactivated bluetongue virus vaccine. Proc. Annu. Meet. US Anim. Health Assoc. (83), 55-62 (1979).
27. Stott JL, Barber TL, Osburn BI. Immunologic response of sheep to inactivated and virulent bluetongue virus. Am. J. Vet. Res. 46(5), 1043-1049 (1985).
28. Schwartz-Cornil I, Mertens PP, Contrera V et al. Bluetongue virus: virology, pathogenesis and immunity. Vet. Res. 39(5), 39-46 (2008).
29. Ramakrishnan M, Pandey AB, Singh KP, Singh R, Nandi S, Mehrotra ML. Immune responses and protective efficacy of binary ethylenimine (BEI)-inactivated bluetongue virus vaccines in sheep. Vet. Res. Comm. 30(8), 873-880 (2006).
30. Pandey AB, Nandi S, Dubey SC et al. Trial of inactivated bluetongue vaccine in Bharat-Merino sheep. J. Immunol. Immunopathol. 8(2), 145-146 (2006).
31. Pandey AB, Nandi S, Audarya SD et al. Effect of inactivated bluetongue vaccine in two different breeds of sheep. Presented at: International Conference on Emerging and Reemerging Viral diseases of the Tropics and Sub-tropics. Indian Agricultural Research Institute, under the auspices of Indian Virological Society, New Delhi, India, 11-14 December 2007.
32. Anon. Bluetongue: second vaccine moves closer to being available. Vet. Rec. 163(4), 99 (2008).
33. Hamers C, Werle-Lapostolle B, Rehbein S et al. Six month efficacy of an inactivated BTV-2 industrial vaccine against a virulent BTV-2 challenge in sheep. In: Proceedings of the Ninth International Symposium on Double-Stranded RNA Viruses. Cape Town, South Africa, 21-26 October 2006.
34. Jime&acuet;nez-Clavero MA, Agu¨ero M, San Miguel E et al. High throughput detection of bluetongue virus by a new real-time fluorogenic reverse transcription-polymerase chain reaction: application on clinical samples from current Mediterranean outbreaks. J. Vet. Diagn. Invest. 18(1), 7-17 (2006).
35. Huismans H, Erasmus BJ. Identification of the serotype specific and groups' specific antigens of bluetongue virus. Onderstepoort J. Vet. Res. 48, 51-58 (1981).
36. Jeggo M, Wright P, Anderson J et al. Review of the IAEA meeting in Vienna on standardization of the cELISA tests and reagents for the diagnosis of bluetongue. In: Bluetongue, African Horse Sickness and Related Orbiviruses. Walton TE, Osburn BI (Eds). Proceedings of: Second International Symposium. 17-21 June 1991, Paris. CRC Press, FL, USA 547-569 (1992).
37. Jeggo MH, Wardley RC. Bluetongue vaccine: cells and or antibodies. Vaccine 3(1), 57-58 (1985).
38. Jeggo MH, Wardley RC, Brownlie J. Importance of ovine cytotoxic T cells in protection against bluetongue virus infection. Prog. Clin. Biol. Res. 178, 477-487 (1985).
39. Odeon AC, Gershwin LJ, Osburn BI. IgE responses to bluetongue virus (BTV) serotype 11 after immunization with inactivated BTV and challenge infection. Comp. Immunol. Microbiol. Infect. Dis. 22(2), 145-162 (1999).
40. MacLachlan NJ. Bluetongue: a review and global overview of the only OIE list A disease that is endemic in North America. In: 55th Annual Meeting of the American College of Veterinary Pathologists (ACVP) & 39th Annual Meeting of the American Society of Clinical Pathology (ASVCP). American College of Veterinary Pathologists & American Society of Veterinary Clinical Pathology (Eds). International Veterinary Information Service, NY, USA 1-5 (2004).
41. McConnell S, Morrill JC, Livingston CW Jr. Use of a quadrivalent modified-live bluetongue virus vaccine in wildlife species. Prog. Clin. Biol. Res. 178, 631-638 (1985).
42. Jeggo MH, Gumm ID, Taylor WP. Clinica and serological response of sheep to serial challenge with different bluetongue virus types. Res. Vet. Sci. 34(2), 205-211 (1983).
43. Wark MC, Shepherd-Clark MB, Smith HV, Collins WD. Laboratory evaluation of a living attenuated vaccine against bluetongue type 20 virus. Aust. Vet. J. 59(1), 6-10 (1982).
44. Hammoumi S, Breard E, Sailleau C et al. Studies on the safety and immunogenicity of the South African bluetongue virus serotype 2 monovalent vaccines: specific detection of the vaccine strain genome by RT-PCR. J. Vet. Med. B Infect. Dis. Vet. Public Health 50(7), 316-321 (2003).
45. Hunter P, Modumo J. A monovalent attenuated serotype 2 bluetongue virus vaccine confers homologous protection in sheep. Onderstepoort J. Vet. Res. 68(4), 331-333 (2001).
46. Lacetera N, Ronchi B. Evaluation of antibody response and nonspecific lymphocyte blastogenesis following inoculation of a live attenuated bluetongue virus vaccine in goats. Am. J. Vet. Res. 65(10), 1331-1334 (2004).
47. Veronesi E, Hamblin C, Mellor PS. Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae). Vaccine 23(48-49), 5509-5516 (2005).
48. Theiler A. The inoculation of sheep against bluetongue and the results in practice. Vet. J. 64, 600-607 (1908).
49. Alexander RA, Haig DA. The use of egg attenuated bluetongue virus in the production of a polyvalent vaccine for sheep: a propagation of the virus in sheep. Onderstepoort J. Vet. Sci. Anim. Ind. 25, 3-15 (1951).
50. Anon. Biennial report of the VRIO: vaccine improvement: 1984-1985. VRIO 54 (1985).
51. Erasmus BJ. The control of bluetongue in an enzootic situation. Aust. Vet. J. 51, 209-210 (1975).
52. Erasmus BJ. The epidemiology and control of bluetongue in South Africa. Bull. Off Int. Epiz. 92, 461-467 (1980).
53. Dungu B, Potgieter C, Von Teichman B, Smit T. Vaccination in the control of bluetongue in endemic regions: the South African experience. Dev. Biol. (Basel) 119, 463-472 (2004).
54. Howell PG. The antigenic classification of strains of bluetongue virus, their significance and use in prophylactic immunization. D.V.Sc. thesis, University of Pretoria, South Africa (1969).
55. Erasmus BJ. Bluetongue virus. In: Virus Infections of Ruminants. Dinter Z, Morein B (Eds). Elsevier, NY, USA 227-237 (1990).
56. Savini G, Tittarelli M, Bonfini B, Zaghini M, Di Ventura M, Monaco F. Serological response in cattle and sheep following infection or vaccination with bluetongue virus. Vet. Ital. 40(4), 645-647 (2004).
57. Savini G, Monaco F, Citarella R et al. Monovalent modified-live vaccine against bluetongue virus serotype 2: immunity studies in cows. Vet. Ital. 40(4), 664-667 (2004).
58. Stelletta C, Cuteri V, Bonizzi L et al. Effect of levamisole administration on bluetongue vaccination in sheep. Vet. Ital. 40(4), 635-639 (2004).
59. OIE Manual. Chapter 2.1.9. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Terrestrial Manual (5th Edition). World Organization for Animal Health Press, Paris, France (2004).
60. Murray PK, Eaton BT. Vaccines for bluetongue. Aust. Vet. J. 73(6), 207-210 (1996).
61. Savini G, Ronchi GF, Leone A et al. An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy. Vet. Microbiol. 124(1-2), 140-146 (2007).
62. Shultz G, Delay PD. Losses in newborn lambs associated with bluetongue vaccination of pregnant ewes. J. Am. Vet. Med. Assoc. 128, 224-226 (1955).
63. MacLachlan NJ, Osburn BI, Stott JL, Ghalib HW. Orbivirus infection of the bovine fetus. Prog. Clin. Biol. Res. 178, 79-84 (1985).
64. MacLachlan NJ, Barrat-Boyes SM, Brewer AW, Stott JL. Bluetongue virus infection in cattle. In: Bluetongue, Africa Horse Sickness and Related Orbiviruses. Walton TE, Osburn BI (Eds). Proceedings of: Second International Symposium. 17-21 June 1991, Paris. CRC Press, FL, USA 725-736 (1992).
65. Barnard BJ, Pienaar JG. Bluetongue virus as a cause of hydranencephaly in cattle. Onderstepoort J. Vet. Res. 43(3), 155-157 (1976).
66. MacLachlan NJ, Osburn BI. Bluetongue virus-induced hydranencephaly in cattle. Vet. Pathol. 20(5), 563-573 (1983).
67. Barrat-Boyes SM, MacLachlan NJ. Pathogenesis of bluetongue virus infection in cattle. J. Am. Vet. Med. Assoc. 206, 1322-1327 (1995).
68. Flanagan M, Johnson SJ. The effects of vaccination of Merino ewes with an attenuated Australian bluetongue virus serotype 23 at different stages of gestation. Aust. Vet. J. 72(12), 455-457 (1995).
69. Osburn BI. The impact of bluetongue virus on reproduction. Comp. Immunol. Microbiol Infect. Dis. 17(3-4), 189-196 (1994).
70. Kirkland PD, Melville LF, Hunt NT, Williams CF, Davis RJ. Excretion of bluetongue virus in cattle semen: a feature of laboratory - adapted virus. Vet. Ital. 40(4), 497-501 (2004).
71. Breard E, Pozzi N, Sailleau C et al. Transient adverse effects of an attenuated bluetongue virus vaccine on the quality of ram semen. Vet. Rec. 160(13), 431-435 (2007).
72. Ferrari G, De Liberato C, Scavia G et al. Active circulation of bluetongue vaccine virus serotype-2 among unvaccinated cattle in central Italy. Prev. Vet. Med. 68(2-4), 103-113 (2005).
73. Monaco F, Cammà C, Serini S, Savini G. Differentiation between field and vaccine strain of bluetongue virus serotype 16. Vet. Microbiol. 116(1-3), 45-52 (2006).
74. Oberst RD, Stott JL, Blanchard-Channell M, Osburn BI. Genetic reassortment of bluetongue virus serotype 11 strain in the bovine. Vet. Microbiol. 15, 11-18 (1987).
75. Samal SK, el-Hussein A, Holbrook FR, Beaty BJ, Ramig RF. Mixed infection of Culicoides variipennis with bluetongue virus serotypes 10 and 17: evidence for high frequency reassortment in the vector. J. Gen. Virol. 68, 2319-2329 (1987).
76. Samal SK, Livingstone CW Jr, McConnell S, Ramig RF. Analysis of mixed infection of sheep with bluetongue serotype 10 and 17: evidence for genetic reassortment in the vertebrate host. J. Virol. 61(4), 1086-1091 (1987).
77. Heidner HW, Iezzi LG, Osburn BI, MacLachlan NJ. Genetic variation and evolutionary relationships amongst bluetongue viruses endemic in the United States. Virus Res. 21, 91-109 (1991).
78. De Mattos CC, de Mattos CA, Osburn BI, MacLachlan NJ. Heterogeneity of the L2 gene of field isolates of bluetongue virus serotype 17 from the San Joaquin Valley of California. Virus Res. 31, 67-87 (1994).
79. Stott JL, Oberst RD, Channell MB, Osburn BI. Genome segment reassortment between two serotypes of bluetongue virus in a natural host. J. Virol. 61, 2670-2674 (1987).
80. Johnson SJ, Polkinghorne IG, Flanagan M, Townsend WL. The Australian experience: results of a bluetongue vaccination program. In: Bluetongue, African Horse Sickness and Related Orbiviruses. Walton TE, Osburn BI (Eds). CRC Press, FL, USA 868-873 (1992).
81. Standfast HA, Dyce AL, Muller MJ. Vectors of BT in Australia. In: Bluetongue and Related Orbiviruses. Barber TL, Jochim MM (Eds). Alan R Liss, NY, USA 177-186 (1985).
82. Giovannini A, Conte A, Panichi G et al. Effects of vaccination against bluetongue on milk production and quality in cattle vaccinated with live attenuated monovalent type 2 vaccines. Vet. Ital. 40(4), 648-653 (2004).
83. Savini G, Monaco F, Facchinei A et al. Field vaccination of sheep with bivalent modified live vaccine against bluetongue virus serotype 2 and 9: effect on milk production. Vet. Ital. 40(4), 627-630 (2004).
84. Monaco F, Bonfini B, Zaghini M, Antonucci D, Pini A, Savini G. Vaccination of cattle using monovalent modified-live vaccine against bluetongue virus serotype 2: innocuity, immunogenicity and effect on pregnancy. Vet. Ital. 40(4), 671-675 (2004).
85. Letchworth GJ, Appleton JA. Passive protection of mice and sheep against bluetongue virus by a neutralizing monoclonal antibody. Infect. Immunol. 39(1), 208-212 (1983).
86. Huismans H. The use of recombinant DNA technology for the development of a bluetongue virus subunit vaccine. Onderstepoort J. Vet. Res. 52(3), 149-151 (1985).
87. Noad R, Roy P. Virus like particles as immunogens. Trends Microbiol. 11(9), 438-444 (2003).
88. Athmaram TN, Bali G, Kahng GG, Dwarakanath S. Heterologous expression of bluetongue VP2 viral protein fragment in Pichia pastoris. Virus Genes 35(2), 265-271 (2007).
89. Van Dijk AA. Development of recombinant vaccines against bluetongue. Biotechnol. Adv. 11(1), 1-12 (1993).
90. Roy P, Urakawa T, Van Dijk AA, Erasmus BJ. Recombinant virus vaccine for bluetongue disease in sheep. J. Virol. 64(5), 1998-2003 (1990).
91. Roy P. Genetically engineered particulate virus-like structures and their use as vaccine delivery systems. Intervirology 39(1-2), 62-71 (1996).
92. French TJ, Marshall JJ, Roy P. Assembly of double-shelled, virus like particles of bluetongue virus by the simultaneous expression of four structural proteins. J. Virol. 64(12), 5695-5700 (1990).
93. Pearson LD, Roy P. Genetically engineered multi-component virus-like particles as veterinary vaccines. Immunol. Cell. Biol. 71(5), 381-389 (1993).
94. Roy P, Bishop DH, Le Blois H, Erasmus BJ. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 12(9), 805-811 (1994).
95. Roy P, French T, Erasmus BJ. Protective efficacy of virus-like particles for bluetongue disease. Vaccine 10 (1), 28-32 (1992).
96. Roy P. From genes to complex structures of bluetongue virus and their efficacy as vaccines. Vet. Microbiol. 33(1-4), 155-168 (1992).
97. Urakawa T, French TJ, Adachi Y et al. Synthesis of recombinant baculoviruses expressing the outer capsid protein VP2 of five BTV serotypes and the induction of neutralizing antibodies to homologous and heterologous BTV serotypes. Virus Res. 31(2), 149-161 (1994).
98. Savini G, Nicolussi P, Pilo G et al. Study of the safety and efficacy of a recombinant vaccine for bluetongue virus serotype 2. Vet. Ital. 43(4), 815-820 (2007).
99. Murphy A, Roy P. Manipulation of the bluetongue virus tubules for immunogen delivery. Future Microbiol. 3, 351-359 (2008).
100. Boone JD, Balasuriya UB, Karaca K et al. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25 (4), 672-678 (2007).
101. Toussaint JF, Sailleau C, Breard E, Zientara S, De Clercq K. Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments. J. Virol. Methods 140(1-2), 115-123 (2007).
102. Perrin A, Albina E, Bread E et al. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 25(37-38), 6774-6783 (2007).
103. Lobato ZI, Coupar BE, Gray CP, Lunt R, Andrew ME. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Vet. Immunol. Immunopathol. 59(3-4), 293-309 (1997).
104. Wade-Evans AM, Romero CH, Mellor P et al. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 220 (1), 227-231 (1996).
105. Larke N, Murphy A, Wirblich C et al. Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen. J. Virol. 79(23), 14822-14833 (2005).
106. Sabine A, Paul R, Roy P, Klenk HD. Induction of T cell response by bluetongue virus core-like particles expressing a T cell epitope of the M1 protein of influenza A virus. Medical Microbiol. Immunol. 187(2), 91-96 (1998).
107. Dhar ML, Dhar MM, Dhawan BN, Mehrotra BN, Roy G. Screening of Indian medicinal plants for biological activity. Indian J. Exp. Biol. 6, 232 (1968).
108. Jassim SAA, Naji MA. A review: novel antiviral agents: a medicinal plant perspective. J. Appl. Microbiol. 95, 412 (2003).
109. Bhanuprakash V, Hosamani M, Balamurugan V, Gandhale P, Swarup D, Singh RK. In-vitro antiviral activity of plant extracts on goatpox virus replication. Indian J. Exp. Biol. 46(2), 128-131 (2008).
110. Balamurugan V, Sen A, Saravanan P et al. Potential effect of aqueous extract of Acacia arabica leaves on peste des petits ruminants (PPR) virus replication. Pharm. Biol. 46(2), 1-9 (2006).
111. Bhanuprakash V, Hosamani M, Balamurugan V, Singh RK, Swarup D. In vitro antiviral activity of Eugenia jambolana plant extract on buffalopox virus: conventional and qPCR methods. Int. J. Trop. Med. 2(1), 3-9 (2007).
112. Smee DF, Sidewell RW, Clark SM, Barnett BB, Spendlove RS. Inhibition of bluetongue and Colorado tick fever orbiviruses by selected antiviral substances. Antimicrob. Agents Chemother. 20 (4), 533-538 (1981).
113. Lazo A, Tassello J, Jayarama V et al. Broad-spectrum virus reduction in red blood cell concentrates using INACTINE PEN10 chemistry. Vox. Sang. 83(4), 313-323 (2002).
114. Goris N, Vandenbussche F, De Clercq K. Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock. Antiviral Res. 78(1), 170-178 (2007).
115. Fulton RW, Rosen-Quist BD. In vitro interferon production by bovine tissues: induction with infectious bovine rhinotracheitis virus. Am. J. Vet. Res. 37, 1497-1502 (1976).
116. Jameson P, Schoenherr CK, Grossberg SE. Bluetongue virus, an exceptionally potent interferon inducer in mice. Infect. Immun. 20(1), 321-323 (1978).
117. Fulton RW, Pearson NJ. Interferon induction in bovine and feline monolayer cultures by four bluetongue virus serotypes. Canadian J. Comp. Med. 46, 100-102 (1982).
118. Taylor JL, O'Brein WJ. Interferon production and sensitivity of rabbit corneal epithelial and stromal cells. Invest. Ophthalmol. Vis. Sci. 26(11), 1502-1508 (1985).
119. World Organization for Animal Health.Role of the OIE in improving animal health by using biotechnologies. OIE Bull. 4, 8-10 (2007).
120. Forzan M, Marsh M, Roy P. Bluetongue virus entry into cells. J. Virol. 81(9), 4819-4827 (2007).
121. Wirblich C, Bhattacharya B, Roy P. Non structural protein 3 of bluetongue virus assists virus release by recruiting ESCRT-I protein Tsg101. J. Virol. 80(1), 460-473 (2006).
122. Scott NR. Nanotechnology and animal health. In: Biotechnology Applications in Animal Health and Production. MacKenzie AA (Ed.). Rev. Off. Int. Epizoot. 24(1), 425-432 (2005).
123. Emidio B, di Nicolussi P, Patta C et al. Efficacy and safety studies on an inactivated vaccine against bluetongue virus serotype 2. Vet. Ital. 40(4), 640-644 (2004).